Stock Ratings / Health Care / ICCC / dividends

IMDX (31) TKNO (44) NNNN (45) MYGN (39) ⌘ Pro Terminal →

ImmuCell Corporation (ICCC) Dividend Safety Gauge & 10-Year DRIP Compounder

$10.32 -2.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.25

ImmuCell Corporation (ICCC) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $93.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.25 (-0.70%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICCC)Realized 20D OHLCV Swing Band: ±4.9%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY ICCC SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 4.28 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)

FRED Regime × Technicals: 77% of 52W Range • RSI-14 at 50.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$9.80+9.7% Next Q

Q2 (-2Q)

Grade D$10.75-4.7% Next Q

Q3 (-1Q)

Grade D$10.25+0.7% Next Q

Current

Grade D$10.32-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ICCC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ICCC currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.04) and Max Pain ($10.84) forces dealer call-delta covering toward $12.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICCC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICCC)

✓Walkthrough of ICCC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.99%📐 WEDGE COMPRESSION COIL

2026-10-30O $10.25H $10.40L $9.98C $10.32VOL 11.0K

RES: $10.78SUP: $9.64SMA50: $10.04SMA200: $8.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICCC Butterfly Map → + Track ICCC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

33.5%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICCC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICCC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCC)

Health Care Rank #349 of 1016 ⚔️ IMDX vs ICCC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICCC vs. IMDX, TKNO, NNNN, MYGN)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ImmuCell Corporation (ICCC) ranks #349 by composite RQD confidence (50/100, grade D) and #669 by equity capitalization ($93.7M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICCC ACTIVE ImmuCell Corporation	D	50/100	—	41.4%	4.2%	-2.82%	$93.7M	Benchmark Subject
IMDX Insight Molecular Diagnostics Inc.	E	31/100	—	56.7%	-35.0%	0.00%	$104.1M	/imdx-vs-iccc →
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-iccc →
NNNN Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-iccc →
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-iccc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000811641

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImmuCell Corporation (ICCC) reported GAAP revenue of $27.6M (+4.3% vs. FY2024 revenue of $26.5M , and +58.2% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of $2.5M, and free cash flow of $1.2M (+1236.0% YoY). On the balance sheet, ICCC closed FY2025 with $42.5M in total assets against $7.5M in total debt (Altman Z-Score: 4.28, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$27.6M	-$1.0M	$2.5M	$1.2M	$42.5M	$7.5M
FY2024 (FY)	2024-12-31	$26.5M	-$2.2M	$357.9K	-$107.8K	$45.1M	$9.0M
FY2023 (FY)	2023-12-31	$17.5M	-$5.8M	-$4.7M	-$4.7M	—	—

3. ICCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ImmuCell Corporation (NASDAQ: ICCC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $10.32 (-2.82% 1D, market cap $93.7M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ICCC ranks #349 in composite RQD confidence.

How does ICCC compare to IMDX and TKNO in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ICCC carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 41.4%, and ROIC of 4.2%. By comparison, IMDX (Insight Molecular Diagnostics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $104.1M) and TKNO (Alpha Teknova Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICCC?

Per ICCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000811641), ImmuCell Corporation generated $27.6M in revenue (+4.3% YoY), -$1.0M in net income, and $1.2M in free cash flow against $42.5M in total assets and $7.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICCC trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCC last traded at $10.32 (-2.82% on volume of 3,319 shares), positioning the stock +2.79% above its 50-day simple moving average ($10.04) and +16.48% above its 200-day simple moving average ($8.86). Across its 52-week range of $4.52 to $12.10, ICCC sits at the 76.5% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±4.9% ($9.81 to $10.83).

ICCC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ICCC pay a dividend and is it safe?

ImmuCell Corporation (ICCC) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ICCC RQD Cockpit ICCC 12M Forecast ICCC Earnings & Move ICCC Dividends & DRIP ICCC Insiders & 13F ICCC Whale Options ICCC Profit Sankey ICCC News & Why